

Scout[®] Research Receives Attention at Recent American Diabetes Association Scientific Sessions

Clinical evidence includes Scout[®] Scores being elevated in diabetic youth

WINNIPEG, Manitoba – July 6, 2015 - Miraculins Inc. (TSX-V: MOM) (“Miraculins” or the “Company”), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, is pleased to announce that four abstracts featuring Scout[®] as a tool for the measurement of skin intrinsic fluorescence (SIF), a marker for pre-diabetes and diabetes, were presented at the recent 75th Scientific Sessions of the American Diabetes Association (ADA) from June 5-9 in Boston, MA. The ADA Scientific Sessions bring together scientists and health care professionals from around the world who are involved in diabetes research and care.

All four of the abstracts, presented as either posters or oral presentations, were as a result of investigator initiated studies where the Scout[®] was selected by leading academic and scientific experts as the device of choice for studies in the flourishing field of research related to skin advanced glycated end products (AGEs) and their role in diabetes.

“It is gratifying to see the Scout[®] embraced by leaders in the diabetes research community and for the device to be playing an essential role in their pioneering work,” said John Maynard, Vice President of Scout[®] Technology for Miraculins and an inventor of the Scout[®]. “These new presentations add to the growing body of clinical data that supports the association of fluorescent biomarkers in the skin, including AGEs, with impaired glucose tolerance and the diabetic condition, and demonstrating the capabilities of the Scout[®] in characterization and measurement of these biomarkers.”

The ADA abstracts which included the Scout[®] are as follows:

Poster Presentations

- *Meta-GWAS Identifies a Second Locus Associated with Skin Intrinsic Fluorescence*, PI A. Patterson, The Hospital for Sick Children, Toronto, ON (#1742-P)
- *Serum Protein Glucosepane and Skin Intrinsic Fluorescence Are increased in Youth with Type 1 Diabetes*, PI RA. Gubitosi-Klug, Case Western Reserve University, Cleveland, OH (#1412-P)
- *Skin Advanced Glycation End Products (AGE) Fluorescence Identifies Abnormal Glucose Tolerance Independent of Levels of HbA1c and Soluble Receptor for Advanced Glycation End Products (sRAGE)* PI V. Mohan, Madras Diabetes Research Foundation & Dr. Mohan's Diabetes Specialties Centre, Chennai, India (#1566-P)

Oral Presentations

- *Advanced Glycation Endproducts (AGEs) Are Already Elevated in Obese Children at Diagnosis of Type 2 Diabetes (T2D)* PI S. Chalew, Louisiana State University Health Sciences Center, New Orleans, LA (#68-OR)

About Miraculins Inc.

Miraculins is a medical diagnostic company focused on acquiring, developing and commercializing non-invasive technologies for unmet clinical needs. The Company's Scout[®] device has been regulatory cleared in certain markets both as a clinical tool to assist in the identification of both prediabetes and type 2 diabetes, and is the first non-invasive testing system designed to provide a highly sensitive and convenient method for measuring prediabetes/type 2 diabetes related biomarkers in the skin, the accumulation of which are accelerated by abnormal blood sugar levels and oxidative stress. Unlike current testing methods, a Scout[®] test requires no blood draw, no fasting, and no waiting for a lab result. The product has been used and validated in thousands of patients around the world. For more information visit www.miraculins.com.

For more information, please contact:

Christopher J. Moreau
President & CEO
Miraculins Inc.
Ph: 204-477-7599
Fax: 204-453-1546

info@miraculins.com
www.miraculins.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, announcement of Scout[®] research, studies and resulting scientific papers, abstracts and posters and presentations of same at industry/public events and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.

These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Miraculins' early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers' willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Miraculins' filings with Canadian securities regulatory authorities, as well as Miraculins' ability to anticipate and manage the risks associated with the foregoing. Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in the body of this news release. Miraculins cautions that the

foregoing list of important factors that may affect future results is not exhaustive. When relying on Miraculins' forward-looking statements to make decisions with respect to Miraculins investors and others should carefully consider the foregoing factors and other uncertainties and potential events.

These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Miraculins cannot provide assurance that actual results will be consistent with these forward-looking statements. Miraculins undertakes no obligation to update or revise any forward-looking statements except as may be required by law.

Scout[®] is a registered trademark of Miraculins Inc. All Rights Reserved. 2015.